Related Experiment Video
Updated: May 2, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
HER-3 expression in HER-2-amplified breast carcinoma
Jacek Czopek1, Janusz Pawlęga2, Kamil Fijorek3
1Department of Pathomorphology, Jagiellonian University, Medical College, Krakow, Poland.
Aim Of The Study:
To determine whether the expression of HER-3 influences the survival of HER-2 positive patients with breast cancer (BC).
Material And Methods:
In the present work, the expression of HER-3 in a group of 35 HER-2 positive patients with BC was studied by performing immunohistochemistry (IHC) in formalin-fixed paraffin embedded tissues.
Results:
Higher HER-3 status if estimated by IHC correlated significantly with older age of the patients. HER-3 expression did not correlate with estrogen or progesterone receptor status, pT or pN. There was also no significant difference in disease-free or overall survival (DFS and OS) between groups with different HER-3 expression, although some tendencies were seen as HER-3 expression in over 50% of cells was a factor of worse 5- and 10-year survival.
Conclusions:
Further studies should be performed on a larger group of patients to confirm the prognostic role of HER-3 status determined by IHC in BC.
